Vaxcyte, Inc.

Under the Lonza Commercial Manufacturing and Supply Agreement, prior to completion of construction and certification of the Suite for commercial operation, we contributed to the capital expenditure costs to construct the Suite (and own certain equipment in the Suite that was purchased or otherwise acquired by us), and paid Lonza a fixed-rate monthly service fee for Lonza s pre-commercial services prior to commencement of commercial operations.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

As of June 30, 2026 and 2025, we have incurred $ 219.8 million and $ 196.3 million of capital expenditures related to the Vaxcyte owned facility buildout and equipment, respectively.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

In addition, we will also pay Thermo Fisher for technology transfer activities and reimburse Thermo Fisher for certain out-of-pocket capital expenditures under the terms of the agreement.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

We are permitted to terminate the Thermo Fisher Commercial Manufacturing and Supply Agreement prior to expiration, subject to the payment of applicable termination fees, plus certain capital expenditure commitments.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our Board.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

As of June 30, 2026 and 2025, no dividends have been declared.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

We are laser-focused on advancing the development of VAX-31 in both adults and infants, given its potential to meaningfully elevate the standard-of-care by broadening protection against invasive pneumococcal disease, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.

SEC original ↗Vaxcyte, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

With a strong balance sheet totaling approximately $2.8 billion in cash, cash equivalents and investments as of the end of the second quarter, we remain focused on advancing VAX-31, our lead candidate and the broadest-spectrum PCV in the clinic today, said Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte.

SEC original ↗Vaxcyte, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

As part of this focused strategy, among other initiatives, we are streamlining activities across our early-stage pipeline while preserving the option to advance promising programs in the future.

SEC original ↗Vaxcyte, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Early-Stage Pipeline Updates Streamlined Early-Stage Pipeline to Prioritize Resources for PCV Programs As part of its continued focus on strategic capital deployment, the Company is prioritizing resources toward its PCV franchise.

SEC original ↗Vaxcyte, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Executive Leadership Team Appointment Appointed Chief Business and Strategy Officer In July, Chris Griffith joined Vaxcyte as Chief Business and Strategy Officer.

SEC original ↗Vaxcyte, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The words anticipate, believe, could, expect, intend, may, on track, potential, should, would and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

SEC original ↗Vaxcyte, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Legal Proceedings 42 Item 1A.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

i Table of Contents Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026

iii Table of Contents Summary of Risks Affecting Our Business Our business is subject to numerous risks and uncertainties, including those discussed more fully in the section titled Risk Factors in this Quarterly Report on Form 10-Q.

SEC original ↗Vaxcyte, Inc. — 10-Q Quarterly report10-QAug 5, 2026